Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Leukemia. 2022 Jan;36(1):292-295. doi: 10.1038/s41375-021-01360-9. Epub 2021 Jul 24.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azetidines / pharmacology*
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism*
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / pathology
  • Graft vs Host Disease / prevention & control*
  • Intestines / drug effects*
  • Intestines / injuries
  • Intestines / pathology
  • Janus Kinase 3 / antagonists & inhibitors*
  • Mice
  • Purines / pharmacology*
  • Pyrazoles / pharmacology*
  • Sulfonamides / pharmacology*
  • T-Lymphocytes, Regulatory / immunology*

Substances

  • Azetidines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • EGFR protein, mouse
  • ErbB Receptors
  • Jak3 protein, mouse
  • Janus Kinase 3
  • baricitinib